{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06706076\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SOLARA","nct_id":"NCT06706076","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=solara-nct06706076. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"SOLARA","arms":[{"description":"* BH-30643 monotherapy for dose escalation\n* BH-30643 monotherapy for dose expansion/optimization at doses determined from dose escalation data","label":"Phase 1 Monotherapy Dose Escalation and Expansion","type":"EXPERIMENTAL"},{"description":"* BH-30643 combo therapy with Carboplatin/Pemetrexed for dose escalation\n* BH-30643 combo therapy with Carboplatin/Pemetrexed for dose expansion /optimization at doses determined from dose escalation data","label":"Phase 1 Combination Dose Escalation and Expansion","type":"EXPERIMENTAL"},{"description":"BH-30643 administered at the RP2D dose determined in Phase 1","label":"Phase 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-07-31","type":"ESTIMATED"},"conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"enrollment":{"count":675,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BH-30643","type":"DRUG"},{"name":"BH-30643 combo therapy with Carboplatin/Pemetrexed","type":"DRUG"},{"name":"BH-30643","type":"DRUG"}],"last_update":"2026-08-05","lead_sponsor":"BlossomHill Therapeutics","official_title":"A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2029-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)","timeFrame":"Within the first 21 days of the first dose of BH-30643."},{"measure":"Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)","timeFrame":"Within 21 days of last participant dosed during Dose Expansion/Optimization."},{"measure":"Objective Response Rate (ORR) (Phase 2)","timeFrame":"Approximately 3 years after the first participant dosed."}],"references":[],"start_date":{"date":"2025-01-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","url":"https://clinicaltrials.gov/study/NCT06706076"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/solara-nct06706076"}